European equities closed mixed on Thursday, with investors taking a spike in US inflation to 5% in May from 4.2% in April, above expectations of 4.7%, and a rate decision by the European Central Bank, while the central bank maintained its accelerated pace … asset purchases.
The French CAC fell 0.3%, the European STOXX 600 added 0.1% and the Swiss market index climbed 0.2%. Meanwhile, the German DAX 30 was down 0.6% and the FTSE 100 added 0.1%.
The ECB maintained its current policy and interest rates, adding only that procurement under its pandemic emergency procurement program will remain at a higher pace in the coming quarter. The purchase of net assets will continue unchanged under the € 1.850 trillion ($ 2.252 trillion) program at least until the end of March 2022, or when the pandemic ends.
The volume of net purchases under the asset purchase program will continue at € 20 billion per month. The ECB’s interest rate on major refinancing operations and interest rates on the margin line and deposit line remain unchanged at 0%, 0.25% and -0.50%, respectively.
The European Parliament has called for the temporary lifting of intellectual property protection for COVID-19 vaccines to increase the supply and availability of injections worldwide. The resolution, which received 355 votes against 263 with 71 abstentions, proposes to start negotiations on the temporary withdrawal of the TRIPS agreement of the World Trade Organization on Patents. He also calls on the United Kingdom and the United States to lift the export ban on vaccines and raw materials.
Meanwhile, the Indian government is expected to provide compensation to COVID-19 vaccine manufacturers such as Pfizer (PFE.F), Reuters reported, citing three government sources. While selling its vaccine to other countries, Pfizer did not do so without receiving compensation due to lawsuits related to the side effects of the vaccine developed in conjunction with BioNTech (22UA.F). Pfizer shares gained 2.3% and BioNTech shares closed slightly lower.
Biotech company Moderna (0QF.F) has asked the FDA to approve a COVID-19 vaccine for emergency use in adolescents aged 12-18. The manufacturer said it has already applied for regulatory approval in Canada and the European Union. Moderna shares fell 2.8%.
On the corporate front, Halma (HLMA.L) said it was confident in the year ahead following a strong start to fiscal 2022 as it reported growth in fiscal 2021 despite a decline in revenue weighted towards the second half and impacted by negative restatement effects. currency. Halma shares closed unchanged.